RA
SUPN icon

Rational Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Rational Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,500
Closed -$60K – 366
2017
Q3 		$60K Buy
+1,500
New +$64.9K 0.03% 286
2016
Q3 		– Sell
-8,400
Closed -$171K – 303
2016
Q2 		$171K Buy
+8,400
New +$149K 0.12% 119

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Rational Advisors's SUPN Position: Q4 2017 in Review

Rational Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q4 2017, closing a stake of 1,500 shares — an estimated $60K sold.

Rational Advisors first reported a position in SUPN in Q2 2016 and held it in 2 quarters. The position peaked at $171K in Q2 2016. 297 funds tracked by Wall St. Rank hold SUPN as of Q4 2017.

  • Rational Advisors reported no remaining Supernus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Rational Advisors sold 1,500 Supernus Pharmaceuticals shares in Q4 2017, an estimated $60K.
  • Rational Advisors first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 2 quarters.
  • Rational Advisors's Supernus Pharmaceuticals position peaked at $171K in Q2 2016.
  • 297 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2017.

Based on Rational Advisors's 13F filing for Q4 2017, filed 8 Feb 2018.